Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study

dc.contributor.author	Bandelow, Borwin
dc.contributor.author	Chouinard, Guy
dc.contributor.author	Bobes, Julio
dc.contributor.author	Ahokas, Antti
dc.contributor.author	Eggens, Ivan
dc.contributor.author	Liu, Sherry
dc.contributor.author	Eriksson, Hans
dc.date.accessioned	2013-01-30T09:59:10Z
dc.date.available	2013-01-30T09:59:10Z
dc.date.issued	2010
dc.identifier.citation	International Journal of Neuropsychopharmacology, 13(3), p. 305-320 (2010); doi:10.1017/S1461145709990423	spa
dc.identifier.issn	1461-1457
dc.identifier.uri	http://hdl.handle.net/10651/6622
dc.description.sponsorship	This study (Silver: D1448C00011) was supported by AstraZeneca Pharmaceuticals.
dc.format.extent	p. 305-320	spa
dc.language.iso	eng
dc.relation.ispartof	International Journal of Neuropsychopharmacology	spa
dc.rights	© 2015 Collegium Internationale Neuro-Psychopharmacologicum
dc.rights	CC Reconocimiento - No comercial - Sin obras derivadas 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	WOK	spa
dc.title	Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study	spa
dc.type	journal article
dc.identifier.local	20100334	spa
dc.identifier.doi	10.1017/S1461145709990423
dc.relation.publisherversion	http://dx.doi.org/10.1017/S1461145709990423	spa
dc.rights.accessRights	open access

Este ítem está sujeto a una licencia Creative Commons